Veru Eyes Development of Combo Treatment to Prevent Muscle Loss, Up Fat Loss with GLP-1 Drugs

 Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of obesity, oncology, and viral induced acute respiratory distress syndrome, today announced it will host an investor conference call and audio webcast on Thursday, January 4, 2024, at 8:00 a.m. ET to discuss the recent financing and the Company’s strategy to prioritize the development of enobosarm for weight loss as well as provide an update on the Company’s drug pipeline.

The audio webcast will be accessible under “Investor Kit” in the Investors page of the Company’s website at www.verupharma.com. To join the conference call via telephone, please dial 1-800-341-1602 (domestic) or 1-412-902-6706 (international) and ask to join the Veru Inc. call. An archived version of the audio webcast will be available for replay on the Company’s website for approximately three months. A telephonic replay will be available on January 4, 2024 at approximately 12:00 p.m. ET by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international), passcode 7752713, for one week.

https://www.biospace.com/article/releases/veru-to-host-investor-call-on-january-4th-2024-to-discuss-recent-financing-and-strategy-to-prioritize-the-development-of-enobosarm-as-a-combination-treatment-to-prevent-muscle-loss-and-augment-fat-loss-associated-with-weight-loss-glp-1-drugs/